Julie Jordan - 20 Feb 2026 Form 4 Insider Report for Neurogene Inc. (NGNE)

Reporting relationship: Chief Medical Officer
Issuer ticker: NGNE
Reported as of: 20 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Feb 2026, 18:49:24 UTC
Prior SEC filing: 28 Mar 2025
Next SEC filing: 30 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Donna M. Cochener, as attorney-in-fact for Julie Jordan

Key filing fact

Julie Jordan filed Form 4 for Neurogene Inc. (NGNE) on 24 Feb 2026.

Key facts

This page summarizes Julie Jordan's Form 4 filing for Neurogene Inc. (NGNE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Feb 2026, 18:49.

Change

Previous filing in this sequence was filed on 28 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001968554 Primary reporting owner

Jordan Julie

Relationship: Chief Medical Officer
Address: C/O NEUROGENE INC., 535 W 24TH STREET, 5TH FLOOR, NEW YORK
Signature: /s/ Donna M. Cochener, as attorney-in-fact for Julie Jordan
Signature date: 24 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NGNE transaction

Common Stock

Award

Transaction value: $0
Shares: +4,900
Change %: +58%
Price: $0.000000
Shares after: 13,300
Date: 20 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NGNE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +29,600
Change %
Price: $0.000000
Shares after: 29,600
Date: 20 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 29,600
Exercise price: $17.64
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Consist of 4,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

Footnote F2

Consist of (a) 8,400 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (b) 4,900 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.

Footnote F3

This option represents the right to purchase 29,600 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.